Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with an emergent ESR1 tumor mutation, phase III SERENA-6 trial finds
https://cancerletter.com/clinical-roundup/20260605_9d/
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment. To access this subscriber-only content please log in or […]
